article thumbnail

Nanorobot hand made of DNA grabs viruses for diagnostics and blocks cell entry

Science Daily: Pharmacology News

A tiny, four-fingered 'hand' folded from a single piece of DNA can pick up the virus that causes COVID-19 for highly sensitive rapid detection and can even block viral particles from entering cells to infect them, researchers report.

DNA 299
article thumbnail

Residue-Selective Inhibitors Discovery via Covalent DNA-Encoded Chemical Libraries with Diverse Warheads

Covalent Modifiers

5c01712 Covalent small molecule drugs have emerged as a crucial support in precision therapy due to their high selectivity and robust potency. Covalent DNA-encoded chemical library (CoDEL) technology is an advanced platform for covalent drug discovery.

DNA 147
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Rational Design of CDK12/13 and BRD4 Molecular Glue Degraders

Covalent Modifiers

While molecular glue degraders exhibit drug-like properties, their discovery has traditionally been serendipitous and often requires post-hoc rationalization. [link] Targeted protein degradation (TPD) is an emerging therapeutic approach for the selective elimination of disease-related proteins.

article thumbnail

Reviewing the IDH1 Mutation‐Mediated Mechanism of Drug Resistance and Revisiting Its Overcoming Strategies

Chemical Biology and Drug Design

At present, there are few studies on the drug resistance of mIDH1 inhibitors. It is found that a significant cause for drug resistance is that IDH1 has mutation at the second site. Isocitrate dehydrogenase (IDH) is a key metabolic enzyme that catalyzes the conversion of isocitrate to -ketoglutaric acid (-KG).

article thumbnail

Allosteric Covalent Inhibitors of the STAT3 Transcription Factor from Virtual Screening

Covalent Modifiers

The modular structure of STAT3 nominates several of its protein domains as possible drug targets, but their exploitation with potential small-molecule inhibitors has been unevenly distributed so far, with past efforts highly favoring the conserved SH2 domain.

article thumbnail

Covalent Destabilizing Degrader of AR and AR-V7 in Androgen-Independent Prostate Cancer Cells

Covalent Modifiers

Currently, drugs and drug candidates against AR target the steroid-binding domain to antagonize or degrade AR. Nomura Journal of the American Chemical Society 2025 DOI: 10.1021/jacs.5c02801

DNA 130
article thumbnail

NGS is evolving: collaboration and tech lead the way

Drug Target Review

Such alliances are already being operationalised, yielding innovations that accelerate diagnostic research in oncology, infectious diseases, reproductive health and other critical therapeutic domains, while simultaneously advancing NGS‐driven approaches for drug discovery. hours to 24 hours. Mybeckman.uk. 2025 [cited 2025 Jun 11].

RNA 91